HTG Molecular Diagnostics Ownership 2024 | Who Owns HTG Molecular Diagnostics Now?

Overview ForecastChart

Institutional Ownership

0.00%

Insider Ownership

6.54%

Retail Ownership

93.46%

Institutional Holders

1.00

HTG Molecular Diagnostics Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
VANGUARD GROUP INC	1.65%	-	14,692	14,692	100.00%	39,668,000	Mar 31, 2023
UBS GROUP AG	0.58%	-	5,198	3,223	163.19%	14,034,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.17%	0.00%	1,481	-5,208	-77.86%	4,000	Mar 31, 2023
BLACKROCK INC.	0.14%	-	1,289	-4,815	-78.88%	3,480,000	Mar 31, 2023
MORGAN STANLEY	0.10%	-	884	-	-	2,387,000	Mar 31, 2023
HIGHMARK WEALTH MANAGEMENT LLC	0.07%	0.00%	580	-	-	1,566,000	Mar 31, 2023
NORDWAND ADVISORS, LLC	0.06%	0.00%	500	500	100.00%	1,350,000	Mar 31, 2023
ALLWORTH FINANCIAL LP	0.03%	-	279	2	0.72%	754,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	13	9	225.00%	35,000	Mar 31, 2023
TCI WEALTH ADVISORS, INC.	0.00%	-	2	-	-	6,000	Mar 31, 2023

HTG Molecular Diagnostics's largest institutional shareholder is VANGUARD GROUP INC, holding 1.65% of the company's total share outstanding, currently valued at $39.67M. The top 10 institutional shareholders own together 2.80% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
HIGHMARK WEALTH MANAGEMENT LLC	0.07%	0.00%	580	-	-	1,566,000	Mar 31, 2023
NORDWAND ADVISORS, LLC	0.06%	0.00%	500	500	100.00%	1,350,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.17%	0.00%	1,481	-5,208	-77.86%	4,000	Mar 31, 2023
ALLWORTH FINANCIAL LP	0.03%	-	279	2	0.72%	754,000	Mar 31, 2023
UBS GROUP AG	0.58%	-	5,198	3,223	163.19%	14,034,000	Mar 31, 2023
VANGUARD GROUP INC	1.65%	-	14,692	14,692	100.00%	39,668,000	Mar 31, 2023
TCI WEALTH ADVISORS, INC.	0.00%	-	2	-	-	6,000	Mar 31, 2023
MORGAN STANLEY	0.10%	-	884	-	-	2,387,000	Mar 31, 2023
BLACKROCK INC.	0.14%	-	1,289	-4,815	-78.88%	3,480,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	13	9	225.00%	35,000	Mar 31, 2023

The largest HTG Molecular Diagnostics shareholder by % of total assets is HIGHMARK WEALTH MANAGEMENT LLC. The company owns 580.00 shares of HTG Molecular Diagnostics (HTGM), representing 0.00% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
VANGUARD GROUP INC	1.65%	-	14,692	14,692	100.00%	39,668,000	Mar 31, 2023
UBS GROUP AG	0.58%	-	5,198	3,223	163.19%	14,034,000	Mar 31, 2023
NORDWAND ADVISORS, LLC	0.06%	0.00%	500	500	100.00%	1,350,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	13	9	225.00%	35,000	Mar 31, 2023
ALLWORTH FINANCIAL LP	0.03%	-	279	2	0.72%	754,000	Mar 31, 2023
MORGAN STANLEY	0.10%	-	884	-	-	2,387,000	Mar 31, 2023
TCI WEALTH ADVISORS, INC.	0.00%	-	2	-	-	6,000	Mar 31, 2023
HIGHMARK WEALTH MANAGEMENT LLC	0.07%	0.00%	580	-	-	1,566,000	Mar 31, 2023
BLACKROCK INC.	0.14%	-	1,289	-4,815	-78.88%	3,480,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.17%	0.00%	1,481	-5,208	-77.86%	4,000	Mar 31, 2023

As of Mar 31 2023, HTG Molecular Diagnostics's largest institutional buyer is VANGUARD GROUP INC. The company purchased 14.69K stocks of HTGM, valued at $39.67M.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
TOWER RESEARCH CAPITAL LLC (TRC)	0.17%	0.00%	1,481	-5,208	-77.86%	4,000	Mar 31, 2023
BLACKROCK INC.	0.14%	-	1,289	-4,815	-78.88%	3,480,000	Mar 31, 2023
HIGHMARK WEALTH MANAGEMENT LLC	0.07%	0.00%	580	-	-	1,566,000	Mar 31, 2023
TCI WEALTH ADVISORS, INC.	0.00%	-	2	-	-	6,000	Mar 31, 2023
MORGAN STANLEY	0.10%	-	884	-	-	2,387,000	Mar 31, 2023
ALLWORTH FINANCIAL LP	0.03%	-	279	2	0.72%	754,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	13	9	225.00%	35,000	Mar 31, 2023
NORDWAND ADVISORS, LLC	0.06%	0.00%	500	500	100.00%	1,350,000	Mar 31, 2023
UBS GROUP AG	0.58%	-	5,198	3,223	163.19%	14,034,000	Mar 31, 2023
VANGUARD GROUP INC	1.65%	-	14,692	14,692	100.00%	39,668,000	Mar 31, 2023

As of Mar 31 2023, HTG Molecular Diagnostics's biggest institutional seller is TOWER RESEARCH CAPITAL LLC (TRC). The company sold -5.21K shares of HTGM, valued at $4.00K.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
VANGUARD GROUP INC	1.65%	-	14,692	14,692	100.00%	39,668,000	Mar 31, 2023
NORDWAND ADVISORS, LLC	0.06%	0.00%	500	500	100.00%	1,350,000	Mar 31, 2023

HTG Molecular Diagnostics's largest new institutional shareholder by number of shares is VANGUARD GROUP INC, purchased 14.69K shares, valued at $39.67M, as of undefined.

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date

HTG Molecular Diagnostics Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
T. Rowe Price Health Sciences Fund, Inc.	0.30%	989,073	-	-	Mar 31, 2024
T. Rowe Price Equity Series, Inc.	0.04%	66,512	-	-	Mar 31, 2024
FIDELITY SELECT PORTFOLIOS	0.03%	1,826,043	-	-	Feb 29, 2024
World Funds Trust	0.01%	62,500	-	-	Jan 31, 2024
VANGUARD INDEX FUNDS	0.00%	1,403,374	-	-	Mar 31, 2024
FIDELITY CONCORD STREET TRUST	0.00%	377,821	-	-	Feb 29, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS	0.00%	30,070	-	-	Mar 31, 2024
SCHWAB CAPITAL TRUST	0.00%	18,640	-	-	Feb 29, 2024
VALIC Co I	0.00%	91,620	-	-	Feb 29, 2024
USAA MUTUAL FUNDS TRUST	0.00%	9,888	-	-	Jan 31, 2024
EQ ADVISORS TRUST	0.00%	34,686	-	-	Mar 31, 2024
JOHN HANCOCK VARIABLE INSURANCE TRUST	0.00%	439	-	-	Mar 31, 2024

HTG Molecular Diagnostics's largest mutual fund holder by % of total assets is "T. Rowe Price Health Sciences Fund, Inc.", owning 989.07K shares, compromising 0.30% of its total assets.

HTG Molecular Diagnostics Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
31 Mar, 21	1	-
31 Dec, 20	1	-96.15%
30 Sep, 20	26	-
30 Jun, 20	26	-13.33%
31 Mar, 20	30	11.11%
31 Dec, 19	27	-34.15%
30 Sep, 19	41	-2.38%
30 Jun, 19	42	10.53%
31 Mar, 19	38	-19.15%
31 Dec, 18	47	-12.96%
30 Sep, 18	54	28.57%
30 Jun, 18	42	7.69%
31 Mar, 18	39	143.75%
31 Dec, 17	16	-20.00%
30 Sep, 17	20	11.11%
30 Jun, 17	18	-10.00%
31 Mar, 17	20	66.67%
31 Dec, 16	12	-45.45%
30 Sep, 16	22	-
30 Jun, 16	22	10.00%
31 Mar, 16	20	5.26%
31 Dec, 15	19	-13.64%
30 Sep, 15	22	-
30 Jun, 15	22	-

As of 31 Mar 21, 1 institutions are holding HTG Molecular Diagnostics's shares, representing an increase of 0.00% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
31 Mar, 21	466	-
31 Dec, 20	466	-100.00%
30 Sep, 20	15,478,134	12.29%
30 Jun, 20	13,783,735	-22.62%
31 Mar, 20	17,812,426	-6.18%
31 Dec, 19	18,985,882	-15.20%
30 Sep, 19	22,389,382	73.27%
30 Jun, 19	12,921,473	0.04%
31 Mar, 19	12,915,872	-11.16%
31 Dec, 18	14,537,695	9.72%
30 Sep, 18	13,249,829	-4.99%
30 Jun, 18	13,946,022	24.98%
31 Mar, 18	11,158,824	445.75%
31 Dec, 17	2,044,669	8.73%
30 Sep, 17	1,880,489	-24.16%
30 Jun, 17	2,479,616	-16.88%
31 Mar, 17	2,983,120	3.30%
31 Dec, 16	2,887,834	-13.50%
30 Sep, 16	3,338,475	-1.84%
30 Jun, 16	3,401,108	-2.87%
31 Mar, 16	3,501,461	-4.85%
31 Dec, 15	3,680,034	-53.64%
30 Sep, 15	7,938,570	114.84%
30 Jun, 15	3,695,159	-

HTG Molecular Diagnostics (HTGM) has 466.00 shares outstanding as of 31 Mar 21, up 0.00% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
31 Mar, 21	0.00%	1000000.00%
31 Dec, 20	0.00%	0.27%
30 Sep, 20	0.15%	701.24%
30 Jun, 20	0.15%	396.56%
31 Mar, 20	0.19%	459.45%
31 Dec, 19	0.20%	352.16%
30 Sep, 19	0.24%	1246.55%
30 Jun, 19	0.14%	720.23%
31 Mar, 19	0.14%	568.03%
31 Dec, 18	0.16%	769.96%
30 Sep, 18	0.14%	633.40%
30 Jun, 18	0.15%	1041.50%
31 Mar, 18	0.12%	24806.82%
31 Dec, 17	0.02%	5382.67%
30 Sep, 17	0.02%	2840.45%
30 Jun, 17	0.03%	2589.41%
31 Mar, 17	0.03%	3321.54%
31 Dec, 16	0.03%	2409.47%
30 Sep, 16	0.04%	2681.97%
30 Jun, 16	0.04%	2576.39%
31 Mar, 16	0.04%	2402.78%
31 Dec, 15	0.04%	542.86%
30 Sep, 15	0.09%	5411.59%
30 Jun, 15	0.04%	-

As of 31 Mar 21, HTG Molecular Diagnostics is held by 0.00% institutional shareholders, representing a 1000000.00% growth compared to 31 Dec 20.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
31 Mar, 21	-	-
31 Dec, 20	-	-100.00%
30 Sep, 20	13	-18.75%
30 Jun, 20	16	-
31 Mar, 20	16	14.29%
31 Dec, 19	14	-39.13%
30 Sep, 19	23	21.05%
30 Jun, 19	19	18.75%
31 Mar, 19	16	-42.86%
31 Dec, 18	28	-15.15%
30 Sep, 18	33	26.92%
30 Jun, 18	26	-21.21%
31 Mar, 18	33	312.50%
31 Dec, 17	8	-42.86%
30 Sep, 17	14	55.56%
30 Jun, 17	9	-10.00%
31 Mar, 17	10	100.00%
31 Dec, 16	5	-
30 Sep, 16	5	-28.57%
30 Jun, 16	7	75.00%
31 Mar, 16	4	-20.00%
31 Dec, 15	5	-54.55%
30 Sep, 15	11	-50.00%
30 Jun, 15	22	-

- institutional shareholders have increased their position in HTGM stock as of 31 Mar 21 compared to - in the previous quarter (a 0.00% increase).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
31 Mar, 21	-	-100.00%
31 Dec, 20	1	-80.00%
30 Sep, 20	5	66.67%
30 Jun, 20	3	-57.14%
31 Mar, 20	7	16.67%
31 Dec, 19	6	-33.33%
30 Sep, 19	9	-35.71%
30 Jun, 19	14	-
31 Mar, 19	14	40.00%
31 Dec, 18	10	-16.67%
30 Sep, 18	12	71.43%
30 Jun, 18	7	-
31 Mar, 18	-	-100.00%
31 Dec, 17	2	-
30 Sep, 17	2	-33.33%
30 Jun, 17	3	-
31 Mar, 17	3	200.00%
31 Dec, 16	1	-88.89%
30 Sep, 16	9	50.00%
30 Jun, 16	6	-33.33%
31 Mar, 16	9	200.00%
31 Dec, 15	3	200.00%
30 Sep, 15	1	-
30 Jun, 15	-	-

- institutional shareholders have reduced their position in HTGM stock as of 31 Mar 21 compared to 1 in the previous quarter (a -100.00% decrease).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
31 Mar, 21	1	-	466	-	0.00%	1000000.00%	-	-	-	-100.00%
31 Dec, 20	1	-96.15%	466	-100.00%	0.00%	0.27%	-	-100.00%	1	-80.00%
30 Sep, 20	26	-	15,478,134	12.29%	0.15%	701.24%	13	-18.75%	5	66.67%
30 Jun, 20	26	-13.33%	13,783,735	-22.62%	0.15%	396.56%	16	-	3	-57.14%
31 Mar, 20	30	11.11%	17,812,426	-6.18%	0.19%	459.45%	16	14.29%	7	16.67%
31 Dec, 19	27	-34.15%	18,985,882	-15.20%	0.20%	352.16%	14	-39.13%	6	-33.33%
30 Sep, 19	41	-2.38%	22,389,382	73.27%	0.24%	1246.55%	23	21.05%	9	-35.71%
30 Jun, 19	42	10.53%	12,921,473	0.04%	0.14%	720.23%	19	18.75%	14	-
31 Mar, 19	38	-19.15%	12,915,872	-11.16%	0.14%	568.03%	16	-42.86%	14	40.00%
31 Dec, 18	47	-12.96%	14,537,695	9.72%	0.16%	769.96%	28	-15.15%	10	-16.67%
30 Sep, 18	54	28.57%	13,249,829	-4.99%	0.14%	633.40%	33	26.92%	12	71.43%
30 Jun, 18	42	7.69%	13,946,022	24.98%	0.15%	1041.50%	26	-21.21%	7	-
31 Mar, 18	39	143.75%	11,158,824	445.75%	0.12%	24806.82%	33	312.50%	-	-100.00%
31 Dec, 17	16	-20.00%	2,044,669	8.73%	0.02%	5382.67%	8	-42.86%	2	-
30 Sep, 17	20	11.11%	1,880,489	-24.16%	0.02%	2840.45%	14	55.56%	2	-33.33%
30 Jun, 17	18	-10.00%	2,479,616	-16.88%	0.03%	2589.41%	9	-10.00%	3	-
31 Mar, 17	20	66.67%	2,983,120	3.30%	0.03%	3321.54%	10	100.00%	3	200.00%
31 Dec, 16	12	-45.45%	2,887,834	-13.50%	0.03%	2409.47%	5	-	1	-88.89%
30 Sep, 16	22	-	3,338,475	-1.84%	0.04%	2681.97%	5	-28.57%	9	50.00%
30 Jun, 16	22	10.00%	3,401,108	-2.87%	0.04%	2576.39%	7	75.00%	6	-33.33%
31 Mar, 16	20	5.26%	3,501,461	-4.85%	0.04%	2402.78%	4	-20.00%	9	200.00%
31 Dec, 15	19	-13.64%	3,680,034	-53.64%	0.04%	542.86%	5	-54.55%	3	200.00%
30 Sep, 15	22	-	7,938,570	114.84%	0.09%	5411.59%	11	-50.00%	1	-
30 Jun, 15	22	-	3,695,159	-	0.04%	-	22	-	-	-

HTG Molecular Diagnostics Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source
Jun 09, 2023	Barat Stephen	officer	Senior VP of Therapeutics	S-Sale	Sell	888	$0.80	$710.40	421

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jun 09, 2023	Barat Stephen	officer	Senior VP of Therapeutics	S-Sale	Sell	888	$0.80	$710.40	421
Apr 07, 2023	Barat Stephen	officer	Senior VP of Therapeutics	F-InKind	Sell	52	$2.70	$140.40	1,309
Feb 10, 2023	Barat Stephen	officer	Senior VP of Therapeutics		Sell	-	-	-	1,361
Feb 10, 2023	Barat Stephen	officer	Senior VP of Therapeutics		Sell	4,166	$62.41	$260.00K	-
Feb 10, 2023	Barat Stephen	officer	Senior VP of Therapeutics		Sell	2,083	$11.28	$23.50K	-

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jun 09, 2023	Barat Stephen	officer	Senior VP of Therapeutics	S-Sale	Sell	888	$0.80	$710.40	421
Apr 07, 2023	Barat Stephen	officer	Senior VP of Therapeutics	F-InKind	Sell	52	$2.70	$140.40	1,309
Feb 10, 2023	Barat Stephen	officer	Senior VP of Therapeutics		Sell	-	-	-	1,361
Feb 10, 2023	Barat Stephen	officer	Senior VP of Therapeutics		Sell	4,166	$62.41	$260.00K	-
Feb 10, 2023	Barat Stephen	officer	Senior VP of Therapeutics		Sell	2,083	$11.28	$23.50K	-
Dec 13, 2022	Lawson Byron	officer	SVP/Chief Commercial Officer	A-Award	Buy	1,000	$0.42	$425.00	6,033
Dec 13, 2022	Lubniewski John L	officer	President & CEO	A-Award	Buy	1,000	$0.42	$425.00	14,133
Dec 13, 2022	McMeans Shaun D	officer	SVP, Finance & Admin. & CFO	A-Award	Buy	1,000	$0.42	$425.00	10,570
Dec 13, 2022	Godlewski Laura Lee	officer	SVP Finance & Administration	A-Award	Buy	1,000	$0.42	$425.00	4,904
Sep 15, 2022	KIRITSY CHRISTOPHER P	director	-	A-Award	Buy	4,000	$0.86	$3.44K	4,000
Sep 15, 2022	GRIFFIN MICHELLE RENEE	director	-	A-Award	Buy	4,000	$0.86	$3.44K	4,000
Sep 15, 2022	McCracken Lee R.	director	-	A-Award	Buy	4,000	$0.86	$3.44K	4,000
Sep 15, 2022	HARDISON DON M	director	-	A-Award	Buy	4,000	$0.86	$3.44K	4,000
Sep 15, 2022	HANHAM ANN	director	-	A-Award	Buy	8,000	$0.86	$6.88K	8,000
Aug 22, 2022	Lawson Byron	officer	SVP/Chief Commercial Officer	A-Award	Buy	20,000	-	-	20,000
Aug 22, 2022	Lawson Byron	officer	SVP/Chief Commercial Officer	A-Award	Buy	20,000	$0.94	$18.80K	20,000
Aug 22, 2022	Godlewski Laura Lee	officer	SVP Finance & Administration	A-Award	Buy	40,000	-	-	40,000
Aug 22, 2022	Godlewski Laura Lee	officer	SVP Finance & Administration	A-Award	Buy	40,000	$0.94	$37.60K	40,000
Aug 22, 2022	McMeans Shaun D	officer	SVP, Finance & Admin. & CFO	A-Award	Buy	60,000	-	-	60,000
Aug 22, 2022	McMeans Shaun D	officer	SVP, Finance & Admin. & CFO	A-Award	Buy	60,000	$0.94	$56.40K	60,000

The last insider sell of HTG Molecular Diagnostics's stock was made by Barat Stephen on Jun 09 2023, selling 888 shares at $0.80 per share (valued at $710.40).

HTG Molecular Diagnostics Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q2 2023	-	1	-
Q1 2023	-	4	-
Q4 2022	4	-	-
Q3 2022	10	1	1000.00%
Q2 2022	4	3	133.33%
Q1 2022	1	3	33.33%
Q4 2021	4	3	133.33%
Q3 2021	6	3	200.00%
Q2 2021	4	3	133.33%
Q1 2021	-	3	-
Q4 2020	5	4	125.00%
Q3 2020	11	4	275.00%
Q2 2020	5	4	125.00%
Q1 2020	6	17	35.29%
Q4 2019	5	4	125.00%
Q3 2019	17	7	242.86%
Q2 2019	6	11	54.55%
Q4 2018	3	6	50.00%
Q3 2018	18	-	-
Q2 2018	4	-	-

0 total buy trades, and 1 total sell trades (buy/sell ratio of 0.00%) were made by HTG Molecular Diagnostics's insiders, as of Q2 2023.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q2 2023	-	1	-
Q1 2023	-	-	-
Q4 2022	-	-	-
Q3 2022	-	-	-
Q2 2022	-	-	-
Q1 2022	-	-	-
Q4 2021	-	-	-
Q3 2021	-	-	-
Q2 2021	-	-	-
Q1 2021	-	-	-
Q4 2020	-	-	-
Q3 2020	-	-	-
Q2 2020	-	-	-
Q1 2020	2	-	-
Q4 2019	-	1	-
Q3 2019	-	-	-
Q2 2019	-	-	-
Q4 2018	-	-	-
Q3 2018	-	-	-
Q2 2018	-	-	-

As of Q2 2023, Insider owners conducted 0 open market buy trades and 1 open market sell trades of HTG Molecular Diagnostics's stocks.

HTG Molecular Diagnostics Peer Ownership

Ticker	Company
GTH	Genetron Holdings Limited
BIOC	Biocept, Inc.
GENE	Genetic Technologies Limited
SQL	SeqLL Inc.
PMD	Psychemedics Corporation
TTOO	T2 Biosystems, Inc.
BIAF	bioAffinity Technologies, Inc.
INBS	Intelligent Bio Solutions Inc.
PRPO	Precipio, Inc.

HTGM Ownership FAQ

Who Owns HTG Molecular Diagnostics?

HTG Molecular Diagnostics is owned by institutional shareholders (0.00%), insiders (6.54%), and public (93.46%). The largest institutional shareholder of HTG Molecular Diagnostics is VANGUARD GROUP INC (1.65% of total shares) and the top mutual fund owner is T. Rowe Price Health Sciences Fund, Inc. (0.30% of total shares).

Who are the major institutional shareholders of HTG Molecular Diagnostics?

HTG Molecular Diagnostics's major institutional shareholders are VANGUARD GROUP INC, UBS GROUP AG, TOWER RESEARCH CAPITAL LLC (TRC), BLACKROCK INC., and MORGAN STANLEY. The top five shareholders own together 2.65% of the company's share outstanding.

How many HTG Molecular Diagnostics shareholders are there?

As of Mar 2021, there are 1 institutional shareholders of HTG Molecular Diagnostics.

What percentage of HTG Molecular Diagnostics is owned by VANGUARD GROUP INC?

VANGUARD GROUP INC owns 14.69K shares of HTG Molecular Diagnostics, representing 1.65% of the company's total shares outstanding, valued at $39.67M (as of Mar 2023).

What percentage of HTG Molecular Diagnostics is owned by UBS GROUP AG?

As of Mar 2023, UBS GROUP AG holds 5.2K shares of HTG Molecular Diagnostics (HTGM), compromising 0.58% of the company, valued at $14.03M.

What percentage of HTG Molecular Diagnostics is owned by TOWER RESEARCH CAPITAL LLC (TRC)?

TOWER RESEARCH CAPITAL LLC (TRC) is the third largest holder of HTG Molecular Diagnostics. The company owns 1.48K of the company's shares outstanding (worth $4K).